Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 185

1.

Mapping HIV-1 vaccine induced T-cell responses: bias towards less-conserved regions and potential impact on vaccine efficacy in the Step study.

Li F, Finnefrock AC, Dubey SA, Korber BT, Szinger J, Cole S, McElrath MJ, Shiver JW, Casimiro DR, Corey L, Self SG.

PLoS One. 2011;6(6):e20479. doi: 10.1371/journal.pone.0020479. Epub 2011 Jun 10.

2.

Control of HIV-1 replication in vitro by vaccine-induced human CD8(+) T cells through conserved subdominant Pol epitopes.

Ahmed T, Borthwick NJ, Gilmour J, Hayes P, Dorrell L, Hanke T.

Vaccine. 2016 Feb 24;34(9):1215-24. doi: 10.1016/j.vaccine.2015.12.021. Epub 2016 Jan 16.

3.

Vaccine-elicited human T cells recognizing conserved protein regions inhibit HIV-1.

Borthwick N, Ahmed T, Ondondo B, Hayes P, Rose A, Ebrahimsa U, Hayton EJ, Black A, Bridgeman A, Rosario M, Hill AV, Berrie E, Moyle S, Frahm N, Cox J, Colloca S, Nicosia A, Gilmour J, McMichael AJ, Dorrell L, Hanke T.

Mol Ther. 2014 Feb;22(2):464-75. doi: 10.1038/mt.2013.248. Epub 2013 Oct 31.

4.

Cytolytic T lymphocytes (CTLs) from HIV-1 subtype C-infected Indian patients recognize CTL epitopes from a conserved immunodominant region of HIV-1 Gag and Nef.

Thakar MR, Bhonge LS, Lakhashe SK, Shankarkumar U, Sane SS, Kulkarni SS, Mahajan BA, Paranjape RS.

J Infect Dis. 2005 Sep 1;192(5):749-59. Epub 2005 Jul 27.

PMID:
16088824
5.

Superior control of HIV-1 replication by CD8+ T cells targeting conserved epitopes: implications for HIV vaccine design.

Kunwar P, Hawkins N, Dinges WL, Liu Y, Gabriel EE, Swan DA, Stevens CE, Maenza J, Collier AC, Mullins JI, Hertz T, Yu X, Horton H.

PLoS One. 2013 May 31;8(5):e64405. doi: 10.1371/journal.pone.0064405. Print 2013.

6.

A phase IIA randomized clinical trial of a multiclade HIV-1 DNA prime followed by a multiclade rAd5 HIV-1 vaccine boost in healthy adults (HVTN204).

Churchyard GJ, Morgan C, Adams E, Hural J, Graham BS, Moodie Z, Grove D, Gray G, Bekker LG, McElrath MJ, Tomaras GD, Goepfert P, Kalams S, Baden LR, Lally M, Dolin R, Blattner W, Kalichman A, Figueroa JP, Pape J, Schechter M, Defawe O, De Rosa SC, Montefiori DC, Nabel GJ, Corey L, Keefer MC; NIAID HIV Vaccine Trials Network.

PLoS One. 2011;6(8):e21225. doi: 10.1371/journal.pone.0021225. Epub 2011 Aug 3.

7.
8.

Broad and cross-clade CD4+ T-cell responses elicited by a DNA vaccine encoding highly conserved and promiscuous HIV-1 M-group consensus peptides.

Almeida RR, Rosa DS, Ribeiro SP, Santana VC, Kallás EG, Sidney J, Sette A, Kalil J, Cunha-Neto E.

PLoS One. 2012;7(9):e45267. doi: 10.1371/journal.pone.0045267. Epub 2012 Sep 18.

9.

Induction of human immunodeficiency virus type 1 (HIV-1)-specific T-cell responses in HIV vaccine trial participants who subsequently acquire HIV-1 infection.

Horton H, Havenar-Daughton C, Lee D, Moore E, Cao J, McNevin J, Andrus T, Zhu H, Rubin A, Zhu T, Celum C, McElrath MJ.

J Virol. 2006 Oct;80(19):9779-88.

10.

A Phase I Double Blind, Placebo-Controlled, Randomized Study of the Safety and Immunogenicity of an Adjuvanted HIV-1 Gag-Pol-Nef Fusion Protein and Adenovirus 35 Gag-RT-Int-Nef Vaccine in Healthy HIV-Uninfected African Adults.

Omosa-Manyonyi G, Mpendo J, Ruzagira E, Kilembe W, Chomba E, Roman F, Bourguignon P, Koutsoukos M, Collard A, Voss G, Laufer D, Stevens G, Hayes P, Clark L, Cormier E, Dally L, Barin B, Ackland J, Syvertsen K, Zachariah D, Anas K, Sayeed E, Lombardo A, Gilmour J, Cox J, Fast P, Priddy F.

PLoS One. 2015 May 11;10(5):e0125954. doi: 10.1371/journal.pone.0125954. eCollection 2015.

11.

Short conserved sequences of HIV-1 are highly immunogenic and shift immunodominance.

Yang OO, Ali A, Kasahara N, Faure-Kumar E, Bae JY, Picker LJ, Park H.

J Virol. 2015 Jan 15;89(2):1195-204. doi: 10.1128/JVI.02370-14. Epub 2014 Nov 5.

12.

Therapeutic vaccination expands and improves the function of the HIV-specific memory T-cell repertoire.

Casazza JP, Bowman KA, Adzaku S, Smith EC, Enama ME, Bailer RT, Price DA, Gostick E, Gordon IJ, Ambrozak DR, Nason MC, Roederer M, Andrews CA, Maldarelli FM, Wiegand A, Kearney MF, Persaud D, Ziemniak C, Gottardo R, Ledgerwood JE, Graham BS, Koup RA; VRC 101 Study Team.

J Infect Dis. 2013 Jun 15;207(12):1829-40. doi: 10.1093/infdis/jit098. Epub 2013 Mar 12.

13.

A human immune data-informed vaccine concept elicits strong and broad T-cell specificities associated with HIV-1 control in mice and macaques.

Mothe B, Hu X, Llano A, Rosati M, Olvera A, Kulkarni V, Valentin A, Alicea C, Pilkington GR, Sardesai NY, Rocafort M, Crespo M, Carrillo J, Marco A, Mullins JI, Dorrell L, Hanke T, Clotet B, Pavlakis GN, Felber BK, Brander C.

J Transl Med. 2015 Feb 15;13:60. doi: 10.1186/s12967-015-0392-5.

14.

MRKAd5 HIV-1 Gag/Pol/Nef vaccine-induced T-cell responses inadequately predict distance of breakthrough HIV-1 sequences to the vaccine or viral load.

Janes H, Frahm N, DeCamp A, Rolland M, Gabriel E, Wolfson J, Hertz T, Kallas E, Goepfert P, Friedrich DP, Corey L, Mullins JI, McElrath MJ, Gilbert P.

PLoS One. 2012;7(8):e43396. doi: 10.1371/journal.pone.0043396. Epub 2012 Aug 27.

15.

Low-dose penile SIVmac251 exposure of rhesus macaques infected with adenovirus type 5 (Ad5) and then immunized with a replication-defective Ad5-based SIV gag/pol/nef vaccine recapitulates the results of the phase IIb step trial of a similar HIV-1 vaccine.

Qureshi H, Ma ZM, Huang Y, Hodge G, Thomas MA, DiPasquale J, DeSilva V, Fritts L, Bett AJ, Casimiro DR, Shiver JW, Robert-Guroff M, Robertson MN, McChesney MB, Gilbert PB, Miller CJ.

J Virol. 2012 Feb;86(4):2239-50. doi: 10.1128/JVI.06175-11. Epub 2011 Dec 7.

16.

Development of a DNA vaccine designed to induce cytotoxic T lymphocyte responses to multiple conserved epitopes in HIV-1.

Wilson CC, McKinney D, Anders M, MaWhinney S, Forster J, Crimi C, Southwood S, Sette A, Chesnut R, Newman MJ, Livingston BD.

J Immunol. 2003 Nov 15;171(10):5611-23.

17.

Defining epitope coverage requirements for T cell-based HIV vaccines: theoretical considerations and practical applications.

Currier JR, Robb ML, Michael NL, Marovich MA.

J Transl Med. 2011 Dec 8;9:212. doi: 10.1186/1479-5876-9-212.

18.

Identification of effective subdominant anti-HIV-1 CD8+ T cells within entire post-infection and post-vaccination immune responses.

Hancock G, Yang H, Yorke E, Wainwright E, Bourne V, Frisbee A, Payne TL, Berrong M, Ferrari G, Chopera D, Hanke T, Mothe B, Brander C, McElrath MJ, McMichael A, Goonetilleke N, Tomaras GD, Frahm N, Dorrell L.

PLoS Pathog. 2015 Feb 27;11(2):e1004658. doi: 10.1371/journal.ppat.1004658. eCollection 2015 Feb.

19.

The effect of HLA polymorphisms on the recognition of Gag epitopes in HIV-1 CRF01_AE infection.

Sriwanthana B, Mori M, Tanaka M, Nishimura S, Miura T, Pathipvanich P, Sawanpanyalert P, Ariyoshi K.

PLoS One. 2012;7(7):e41696. doi: 10.1371/journal.pone.0041696. Epub 2012 Jul 27. Erratum in: PLoS One. 2014;9(8):e106978.

20.

Identification of new HIV-1 Gag-specific cytotoxic T lymphocyte responses in BALB/c mice.

Cellini S, Fortini C, Gallerani E, Destro F, Cofano EB, Caputo A, Gavioli R.

Virol J. 2008 Jul 14;5:81. doi: 10.1186/1743-422X-5-81.

Supplemental Content

Support Center